Jim Cramer on Recursion Pharmaceuticals: “It’s a let down, big let down”

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller mentioned that Cathie Wood invested in the stock, Cramer remarked, “That’s, it’s a ...

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...
Zacks Investment Research on MSN

Recursion Pharmaceuticals (RXRX) sees a more significant dip than broader market: Some facts to know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.44, moving -1.99% from the previous trading session. This change lagged the S&P 500's 0.21% loss on the day. Meanwhile, the ...

Is Recursion Pharmaceuticals (RXRX) Pricing Reflect Recent 1‑Year Share Slump Accurately

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

A Look At Recursion Pharmaceuticals (RXRX) Valuation After AI Milestone And Improved Quarterly Results

Recursion Pharmaceuticals (RXRX) is back in focus after reporting fourth quarter and full year 2025 results, highlighting much higher quarterly revenue, a smaller net loss, and fresh commentary on its ...
STAT

Recursion CEO: Biotech’s rainy season is not over — but we must race ahead

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

PacBio Announces the Appointment of Chris Gibson to the Board of Directors

PacBio (NASDAQ: PACB), a leading provider of high-quality, long-read sequencing technologies, today announced the appointment of Christopher Gibson, Ph.D., to PacBio’s Board of Directors. Dr. Gibson ...
MedCity News

AI Biotech Recursion Commits $88M to a Pair of Drug Discovery Acquisitions

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...
The Motley Fool

The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why.

Recursion Pharmaceuticals is merging with Exscientia. The new entity will have the backing of quite a few big names in pharma. It'll also have an even more capable drug discovery and development ...

Recursion Pharmaceuticals’ Earnings Call Highlights AI Momentum

Recursion Pharmaceuticals, Inc ( (RXRX)) has held its Q4 earnings call. Read on for the main highlights of the call.

Recursion outlines extended cash runway into early 2028 as platform efficiency accelerates

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...